KaNDy Therapeutics

KaNDy Therapeutics

KaNDy Therapeutics

A clinical-stage company focused on optimizing the potential ofNT-814 as a non-hormonal breakthrough treatment for multiple symptoms of themenopause.
Founded
2017
Raised
$32.9M
Follow us
Alexa global traffic share
Twitter followers
Acquired by
Bayer
1
11 Aug 2020
$450,000,000
Latest funding
$450,000,000
FinSMEs

Bayer to Buy KaNDy Therapeutics

£25,000,000 Venture capital (Series C)
FinSMEs , MedCity News , PE HUB

KaNDy Therapeutics Raises £25M in Series C Financing

Health Funding